Compare Freeport-McMoRan Inc (FCX) vs Oscar Health Inc (OSCR) Price & Performance

FCX trades at $58.30, down 5.92% over 24 hours, with a neutral technical signal and bearish moving averages. The stock has consistently beaten earnings estimates, with Q2 2026 expected EPS of $0.60. Revenue grew to $25.92B in 2025, with net income of $2.20B and a net margin of 10.34%. The company maintains strong cash flow from operations of $5.61B and a dividend of $0.15 per share payable in August 2026.

FCX presents a favorable outlook with robust earnings performance and analyst consensus pointing to a $72.94 price target, implying significant upside. However, risks include commodity price volatility, high capital expenditures, and debt levels. The stock's current valuation at a P/E of 32.26 may limit near-term gains if growth moderates.

Oscar Health (OSCR) trades at $30.73, down 1.09% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong revenue growth, with 2026 revenue projected at $13.3 billion, but remains unprofitable with a net margin of -0.3%. Recent news highlights its momentum, including a 102.8% year-to-date gain and positive coverage from The Motley Fool and Zacks.

The outlook is mixed: strong revenue growth and bullish technicals offer upside potential, but profitability challenges and a consensus price target below the current price signal caution. Key risks include execution in a competitive insurance market and sustained losses. Analyst sentiment is divided, with a hold-heavy consensus.